<?xml version="1.0" encoding="UTF-8"?><faers xmlns="http://fda.gov/ns/faers"><meta><status>PENDING</status><version>v2</version><patient-age>100</patient-age><report-id>PHHY2012BR113610</report-id><gender>female</gender><reactions><reaction>Unspecified infection</reaction></reactions><drugs><drug><ndc>59572983</ndc><drug-name>EXELON PATCH</drug-name><manufacturer/><ingredients/></drug></drugs><indications><indication>Multiple sclerosis</indication></indications><outcomes><outcome>Death</outcome><outcome>Required Inpatient Hospitalization</outcome></outcomes><country>Brazil</country><geo/></meta><original><ichicsr lang="en" xmlns="">
	<ichicsrmessageheader>
		<messagetype>ichicsr</messagetype>
		<messageformatversion>2.1</messageformatversion>
		<messageformatrelease>2.0</messageformatrelease>
		<messagenumb>4053224_286</messagenumb>
		<messagesenderidentifier>NovartisPH</messagesenderidentifier>
		<messagereceiveridentifier>ZZFDA</messagereceiveridentifier>
		<messagedateformat>204</messagedateformat>
		<messagedate>20121211134651</messagedate>
	</ichicsrmessageheader>
	<safetyreport>
		<safetyreportversion>1</safetyreportversion>
		<safetyreportid>PHHY2012BR113610</safetyreportid>
		<primarysourcecountry>BR</primarysourcecountry>
		<occurcountry>BR</occurcountry>
		<transmissiondateformat>102</transmissiondateformat>
		<transmissiondate>2012-12-11</transmissiondate>
		<reporttype>1</reporttype>
		<serious code="1">Yes</serious>
		<seriousnessdeath>1</seriousnessdeath>
		<seriousnesslifethreatening>2</seriousnesslifethreatening>
		<seriousnesshospitalization>1</seriousnesshospitalization>
		<seriousnessdisabling>2</seriousnessdisabling>
		<seriousnesscongenitalanomali>2</seriousnesscongenitalanomali>
		<seriousnessother>2</seriousnessother>
		<receivedateformat>102</receivedateformat>
		<receivedate>2012-12-08</receivedate>
		<receiptdateformat>102</receiptdateformat>
		<receiptdate>2012-12-08</receiptdate>
		<additionaldocument>2</additionaldocument>
		<fulfillexpeditecriteria>1</fulfillexpeditecriteria>
		<companynumb>PHHY2012BR113610</companynumb>
		<medicallyconfirm>2</medicallyconfirm>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>BR</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<primarysource>
			<reporterfamilyname>PRIVACY</reporterfamilyname>
			<reportercountry>BR</reportercountry>
			<qualification code="5">Consumer or non-health professional</qualification>
		</primarysource>
		<sender>
			<sendertype>1</sendertype>
			<senderorganization>NOVARTIS PHARMACEUTICAL CORPORATION</senderorganization>
			<senderdepartment>Clinical Safety and Epidemiology</senderdepartment>
			<senderfamilyname>Clinical Safety and Epidemiology</senderfamilyname>
			<senderstreetaddress>Novartis Pharmaceuticals Corp. Bldg 419, One Health Plaza</senderstreetaddress>
			<sendercity>East Hanover</sendercity>
			<senderstate>NJ</senderstate>
			<senderpostcode>07936</senderpostcode>
			<sendercountrycode>US</sendercountrycode>
			<sendertel>+1800378</sendertel>
			<sendertelextension>8567</sendertelextension>
			<sendertelcountrycode>US</sendertelcountrycode>
			<senderfax>+1973781</senderfax>
			<senderfaxextension>8001</senderfaxextension>
			<senderfaxcountrycode>US</senderfaxcountrycode>
			<senderemailaddress>gdss.configuration@pharma.novartis.com</senderemailaddress>
		</sender>
		<receiver>
			<receivertype>2</receivertype>
			<receiverorganization>ZZFDA</receiverorganization>
			<receiverdepartment>FDA</receiverdepartment>
			<receivertitle>Mr</receivertitle>
			<receivergivename>William</receivergivename>
			<receiverfamilyname>Taylor</receiverfamilyname>
			<receiverstreetaddress>5600 Fishers Lane Room 16B-45</receiverstreetaddress>
			<receivercity>Rockville</receivercity>
			<receiverstate>MD</receiverstate>
			<receiverpostcode>20857</receiverpostcode>
			<receivercountrycode>US</receivercountrycode>
			<receivertel>+1301827</receivertel>
			<receivertelextension>0964</receivertelextension>
			<receivertelcountrycode>US</receivertelcountrycode>
			<receiverfax>+1301594</receiverfax>
			<receiverfaxextension>0829</receiverfaxextension>
			<receiverfaxcountrycode>US</receiverfaxcountrycode>
			<receiveremailaddress>.</receiveremailaddress>
		</receiver>
		<patient>
			<patientinitial>AA</patientinitial>
			<patientbirthdateformat>102</patientbirthdateformat>
			<patientbirthdate>19121208</patientbirthdate>
			<patientsex code="2">Female</patientsex>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Abdominal discomfort</patientepisodename>
			</medicalhistoryepisode>
			<medicalhistoryepisode>
				<patientepisodenamemeddraversion>15.1</patientepisodenamemeddraversion>
				<patientepisodename>Vomiting</patientepisodename>
			</medicalhistoryepisode>
			<patientdeath>
				<patientdeathdateformat>610</patientdeathdateformat>
				<patientdeathdate>201211</patientdeathdate>
				<patientautopsyyesno>3</patientautopsyyesno>
				<patientdeathcause>
					<patientdeathreportmeddraversion>15.1</patientdeathreportmeddraversion>
					<patientdeathreport>Infection</patientdeathreport>
				</patientdeathcause>
			</patientdeath>
			<reaction>
				<primarysourcereaction>Unspecified infection</primarysourcereaction>
				<reactionmeddraversionllt>15.1</reactionmeddraversionllt>
				<reactionmeddrallt>Infection NOS</reactionmeddrallt>
				<reactionmeddraversionpt>15.1</reactionmeddraversionpt>
				<reactionmeddrapt>Infection</reactionmeddrapt>
				<reactionoutcome code="5">fatal</reactionoutcome>
			</reaction>
			<drug>
				<drugcharacterization code="1">suspsect</drugcharacterization>
				<medicinalproduct>EXELON PATCH</medicinalproduct>
				<obtaindrugcountry>BR</obtaindrugcountry>
				<drugauthorizationnumb>22-083</drugauthorizationnumb>
				<drugauthorizationcountry>BR</drugauthorizationcountry>
				<drugauthorizationholder>NOVARTIS SECTOR: PHARMA</drugauthorizationholder>
				<drugdosagetext>UNK UKN, once a day</drugdosagetext>
				<drugdosageform normalized="trans-therapeutic-system">Trans-therapeutic-system</drugdosageform>
				<drugadministrationroute code="062">Transdermal</drugadministrationroute>
				<drugindicationmeddraversion>15.1</drugindicationmeddraversion>
				<drugindication>Multiple sclerosis</drugindication>
				<actiondrug code="5">Unknown</actiondrug>
				<drugrecurreadministration code="3">Unknown</drugrecurreadministration>
				<activesubstance>
					<activesubstancename>RIVASTIGMINE</activesubstancename>
				</activesubstance>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Infection</drugreactionasses>
					<drugassessmentsource>PHARMACEUTICAL COMPANY</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Not assessable</drugresult>
				</drugreactionrelatedness>
				<drugreactionrelatedness>
					<drugreactionassesmeddraversion>15.1</drugreactionassesmeddraversion>
					<drugreactionasses>Infection</drugreactionasses>
					<drugassessmentsource>PRIMARY SOURCE REPORTER</drugassessmentsource>
					<drugassessmentmethod>Global Introspection</drugassessmentmethod>
					<drugresult>Suspected</drugresult>
				</drugreactionrelatedness>
			</drug>
			<summary>
				<narrativeincludeclinical>Case number PHHY2012BR113610, is an <Semaphore x="1938518" class="Disease or Finding" value="First-Degree Burn" score="1.00" ID="C76130">initial </Semaphore>spontaneous report received from a consumer via marketing program (ID 423 - Vale Mais Saude -<Semaphore x="2684608" class="Occupation" value="Vendor" score="1.00" ID="C68608">Vendor</Semaphore>: Voxline) on 08 Dec 2012. This report refers to a 96-year old female patient. The patient medical history included unspecified <Semaphore x="2586041" class="Disease or Finding" value="Stomach Disorder" score="1.00" ID="C26886">stomach disorder </Semaphore>and use to <Semaphore x="2693861" class="Disease or Finding" value="Vomiting" score="1.00" ID="C3442">vomit </Semaphore>a lot. Since an unknown date the patient was on <Semaphore x="560518" class="Medicine" value="Exelon" score="0.74" ID="249270">Exelon </Semaphore>patch (<Semaphore x="1142851" class="Medicine" value="rivastigmine" score="0.49" ID="239962">rivastigmine</Semaphore>), transdermal for <Semaphore x="2245768" class="Disease or Finding" value="Multiple Sclerosis" score="1.00" ID="C3243">multiple sclerosis </Semaphore>once a day. After the <Semaphore x="2610768" class="Procedure" value="Therapeutic Procedure" score="1.00" ID="C49236">treatment </Semaphore>with <Semaphore x="560518" class="Medicine" value="Exelon" score="0.74" ID="249270">Exelon </Semaphore>patch the patient presented with an unspecified <Semaphore x="3033151" class="MedDRA LLT" value="Infection" score="1.00" ID="10021789">infection</Semaphore>. Due to this, she was hospitalized in Nov 2012. The patient died after 3 days of <Semaphore x="3012166" class="MedDRA LLT" value="Hospitalisation" score="1.00" ID="10054112">hospitalization </Semaphore>in Nov 2012 due to <Semaphore x="3033151" class="MedDRA LLT" value="Infection" score="1.00" ID="10021789">infection</Semaphore>. The <Semaphore x="1558453" class="Disease or Finding" value="Autopsy TNM Finding" score="1.00" ID="C48882">autopsy </Semaphore><Semaphore x="1910095" class="Disease or Finding" value="Experimental Result" score="1.00" ID="C76125">results </Semaphore>were unknown. The causality was not reported.</narrativeincludeclinical>
				<sendercomment>Medical assessment comment: Review of available reported data does not allow for a proper causality assessment. </sendercomment>
			</summary>
		</patient>
	</safetyreport>
</ichicsr></original></faers>